David Hong

Company: MD Anderson Cancer Center

Job title: Deputy Chair, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine

Seminars:

Panel Discussion: Now We Have Successfully Targeted RAS G12C, What’s Next? 5:00 pm

As we close out two days dedicated to critical updates and project successes from across this community, this panel will dive into a discussion considering what is next for therapeutics targeting RAS-mutant cancers. After 40 years of dedicated science and significant progress, it is critical we expand the landscape of RAS targeted therapies beyond G12C…Read more

day: Day Two